RBC, Stifel are joint bookrunners; Canaccord Genuity, Needham assist
By Devika Patel
Knoxville, Tenn., Oct. 25 - Aerie Pharmaceuticals, Inc. said it priced its $67.2 million initial public offering of stock with a $10.08 million greenshoe. The deal was announced Sept. 17.
The company will sell 6.72 million common shares at $10.00 apiece.
RBC Capital Markets and Stifel are the joint bookrunning managers.
Settlement is expected Oct. 30.
Proceeds will be used for clinical trials, working capital and general corporate purposes.
The clinical-stage pharmaceutical company is based in Bedminster, N.J. It intends to list its common stock on the Nasdaq under the symbol "AERI."
| Issuer: | Aerie Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $67.2 million
|
| Greenshoe: | $10.08 million
|
| Shares: | 6.72 million
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunners: | RBC Capital Markets and Stifel
|
| Co-managers: | Canaccord Genuity Inc. and Needham & Co.
|
| Announcement date: | Sept. 17
|
| Pricing date: | Oct. 25
|
| Settlement date: | Oct. 30
|
| Stock exchange: | Nasdaq: AERI
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
